Hikma has succeeded in convincing a US district court to dismiss allegations that it induced infringement of patents protecting a cardiovascular indication for Amarin’s Vascepa (icosapent ethyl) with its skinny-label generic.
Following Hikma’s launch of the first US generic version of Vascepa in November 2020 – in the wake of success...






